Positive 6 Month Results from CroíValve’s TANDEM I Study to Treat Tricuspid Regurgitation Presented at New York Valves 2024
Favorable patient outcomes from the TANDEM I first-in-human clinical trial [...]
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera Pharmaceuticals notes the article titled “Vimseltinib versus placebo for [...]
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a [...]
Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study
The study is designed to assess the clinical utility and [...]
In a Usability Analysis of the ArthroFree Wireless Surgical Camera by Lazurite®, More than 90% of Respondents Agree the Absence of Cables Will Have a Positive Impact on Efficiency and Patient Safety
Medical device and technology company Lazurite® announced that a new [...]
Growth in Use of Proton Therapy for Treating Wider Variety of Conditions | According to New Study Published in Red Journal Reveals Growth
Based on NAPT member survey data and other sources, “Temporal [...]
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
Sensorion notes This gene therapy for patients suffering from otoferlin [...]
AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System | Reports Boston Scientific as First-Line Treatment for Persistent Atrial Fibrillation
The AVANT GUARD clinical trial will evaluate the safety and [...]
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
YOLT-201 Injection utilizes several lipid components including ionizable lipids as [...]
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
“It is encouraging to see positive initial safety results in [...]